Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Healthcare Drugs topic
No spam. Unsubscribe anytime.
Hospitals, clinics and drugmakers clash over 340B contract‑pharmacy rules; committee defers decision
Summary
Senators heard testimony for and against a bill aimed at regulating 340B contract‑pharmacy access, with clinics and hospitals warning of local access problems and manufacturers raising legal concerns; the committee deferred action.
Senators heard extended testimony and sharply differing views on a bill aimed at regulating access to medicines purchased under the federal 340B discount program and distributed through contract pharmacies.
Community health centers, hospital systems and patient advocates said the measure would help ensure patients served by safety‑net providers can obtain discounted drugs locally. "They are 3 patients who live with type 1 diabetes who cannot access insulin at contract pharmacies because there are no manufacturers who are willing to ship it to our contract pharmacies," testified Melissa Boomgaarden, director of pharmacy services for a community health center, describing patients who rely on insulin access.
Drug‑industry representatives said the bill could create legal exposure and does not reflect how 340B is administered nationwide. William Gu of PhRMA told the committee, "Contrary to what the bill may imply, there is no issue regarding accessibility of 340B drugs to covered entities," and raised concerns about whether certain patients at contract pharmacies are entitled to the discount. The Biotechnology Innovation Organization warned that litigation in multiple states raises preemption questions.
Hospitals and health systems said losses tied to 340B access have materially affected local institutions. A Healthcare Association representative estimated tens of millions of dollars—roughly $30 million a year—were at stake for hospitals and federally qualified health centers and urged action to keep funds in the state.
Why it matters: The 340B program enables qualifying providers to purchase outpatient drugs at discounted prices. Disputes about contract pharmacy arrangements and manufacturer distribution affect whether patients served by safety‑net clinics can fill prescriptions locally and whether state health plans or hospitals pay higher prices.
Committee action: The committee heard testimony from trade groups, manufacturers, community health centers and hospitals and took no final vote. Committee members later deferred decision making on SB 480 to allow the House companion or related litigation to proceed and to give stakeholders more time to negotiate language.
What to watch: Sponsors and stakeholders indicated they are working with the attorney general and the Department of Health on possible amendments; senators said they will revisit the measure after companion‑bill activity or if litigation outcomes clarify federal constraints.
Ending: For now, the committee deferred action; proponents and opponents agreed to continue technical negotiations.
